Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Relationship of EPS, Antiparkinsonian Drugs, and TD

John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.
John M. Kane, MD
Rebecca S. Roma, MD
Released: July 20, 2021

In this episode, John M. Kane, MD, and Rebecca S. Roma, MD, discuss clinical assessment of extrapyramidal symptoms (EPS), antiparkinsonian drugs, and tardive dyskinesia (TD). They review differentiating between TD and EPS, identify tools for diagnosing TD, and provide some important clinical pearls and evidence-based reasons for choosing different medications for treating EPS and TD.


John M. Kane, MD
Professor and Chairman
Department of Psychiatry
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Glen Oaks, New York

Rebecca S. Roma, MD
Medical Director
Pittsburgh, Pennsylvania


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant provided by
Neurocrine Biosciences

Related Content

Greg Mattingly, MD, and Manish Jha, MD, review the latest available clinical data for emerging therapy options for tardive dyskinesia, from Clinical Care Options (CCO)

Manish Jha, MBBS Greg Mattingly, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Physician Assistants: maximum of 1.5 hours of AAPA Category I CME credits Psychologists: 1.5 APA CE Credits Social Workers: 1.5 ACE CE Credits Released: October 22, 2021 Expired: October 21, 2022

Clinical Care Options (CCO) commentary by Thomas L. Schwartz, MD, on choosing the right atypical antipsychotic in bipolar I and bipolar II patients

Thomas L. Schwartz, MD Released: October 15, 2021

Attention deficits in a bipolar patient with a history of cannabis use from Clinical Care Options (CCO)

Joseph F. Goldberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I (Preapproved) credit Released: October 7, 2021 Expired: October 6, 2022

Slides from a presentation that educates clinicians on innovations in managing essential tremor and dystonias.

Rajesh Pahwa, MD Released: October 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.